BioSpace News Archive

– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth hormone deficiency diagnostic – – Planned safety and efficacy study AEZS-130-P02 (“Study P02”) of macimorelin expected to commence in Q4 2020 – – Advancing ongoing business development discussions to secure a commercialization partner for macimorelin in Europe and other key global markets –

Digirad Corporation will release its financial results for the first quarter ended March 31, 2020, before the market opens on Friday, May 15, 2020.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020, which this year will be held digitally June 6-8, 2020. The study will be presented by Dr. Marcus Maurer, Professor of Dermatology and Allergy and Director of Research at the Departme

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced the advancement of its medical-grade biosensor product portfolio and Data-as-a-Service (DaaS) platform with the introduction of the BioButton™ device.

May 6, 2020 12:00 UTC Clinically relevant reductions in liver fat content, insulin resistance and fibroinflammation markers observed with AXA1125 along with favorable tolerability, supporting its potential to be a first-line NASH therapy Greater activity in key markers seen among subjects with type 2 diabetes receiving AXA1125 Company plans to engage with FDA regarding IND submission for AXA1125, proposed Phase 2b clinical trial in adult NASH and pediatric dev

Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, has received approximately $5.3 million in net proceeds calendar year to date as a result of the exercise of equity warrants.

- New corporate name, Cardiff Oncology, reflects the Company’s mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients - Effective May 8th, Dr. Thomas Adams will transition his role from Chairman and CEO to Executive Chairman and Dr. Mark Erlander will assume the role of CEO - Changes mark an important milestone in the Company’s evolution and advancing development of onvansertib in cancer indications with the greatest medic

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells), the Company’s lead product candidate for treatment of mucos

- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial results for the first quarter ended March 31, 2020 on Wednesday, May 13, 2020, after the market closes. Following the release, Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, John Gandolf

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept, will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference on Wednesday, May 13, 2020 at 2:20 p.m. ET. A live webcast of the event will b